Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Erlotinib Prevention of Oral Cancer (EPOC)

NCT00402779 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT00402779
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00402779 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Erlotinib Prevention of Oral Cancer (EPOC)
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 3
Overall status
Completed
Start date
November 3, 2006
Completion date
June 4, 2018
Enrollment
303 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

oral cancer